- Coordinator
- Butterfly Medical Ltd, Israel
- Runs
- 1 September 2023 to 31 August 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €4.8m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190156124
What the project is doing
In the project's own words, from its summary on CORDIS.
Butterfly Medical, a medical-device start-up, is developing a fast, simple, and minimally invasive alternative treatment to medication and surgery used for Benign Prostate Hyperplasia (BPH) treatment. Butterflys innovative device transfers the procedure from the operating room to the clinic, with the device being placed in 6 to 8 minutes, in doctors office, under local anaesthesia. Butterflys unique anatomically shaped proprietary nitinol implant is positioned in the prostatic urethra in order to open the urine path in the prostate for improved urine flow thereby relieving BPH symptoms.
Implant doesnt require any resection, cutting, or ablation of prostatic tissue. FIH clinical trials involving 85 patients performed in leading medical centres in Israel show a high degree of safety and effectiveness. Through this EIC project, Butterfly will undertake post-marketing studies in leading medical centres in Europe, and pivotal FDA study in the US.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Butterfly Medical Ltd | Yokneam | Israel | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI